Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments

v3.23.1
Note 14 - Segments
3 Months Ended
Mar. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

14.

Segments

 

We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two primary types of drug products: (i) diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of our Manocept platform, and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform.

 

The information in the following tables is derived directly from each reportable segment’s financial reporting.

 

 

Three Months Ended March 31, 2023

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Research and development expenses

  $ 1,170,553     $ 96,900     $     $ 1,267,453  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          2,178       1,125,183       1,127,361  

Depreciation and amortization (2)

    9,275             18,280       27,555  

Loss from operations (3)

    (1,179,828 )     (99,078 )     (1,143,463

)

    (2,422,369

)

Other expense (4)

                946,039       946,039  

Net loss

    (1,179,828 )     (90,078 )     (197,424

)

    (1,476,330

)

Total assets, net of depreciation and amortization:

                               

United States

  $     $     $ 1,776,386     $ 1,776,386  

International

    578,272             12,928       591,200  

Capital expenditures

    15,068                   15,068  

 

 

Three Months Ended March 31, 2022

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Research and development expenses

  $ 989,887     $ 179,367     $     $ 1,169,254  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

                1,787,152       1,787,152  

Depreciation and amortization (2)

    6,040             16,838       22,878  

Loss from operations (3)

    (995,927 )     (179,367 )     (1,803,990

)

    (2,979,284

)

Other expense (4)

                (7,961 )     (7,961

)

Net loss

    (995,927 )     (179,367 )     (1,811,951

)

    (2,987,245

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 150,920     $     $ 3,034,316     $ 3,185,236  

International

    393,753             23,136       416,889  

Capital expenditures

    40,221             1,796       42,017  

 

 

(1)

General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

 

(2)

Depreciation and amortization are reflected in selling, general and administrative expenses ($27,555 and $22,878 for the three-month periods ended March 31, 2023 and 2022, respectively).

 

(3)

Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

 

(4)

Amounts consist primarily of gain on amendment of contracts, interest income and interest expense, which are not currently allocated to our individual reportable segments.